

Figure 1

Schematic of cloning step used in library construction




Figure 2

Primer sequences used in library construction

YOL22	cattttcagggatagcaagc	SEQ ID No: 1
TRBV6-5	ttctattctcacagcgcggaatgctggtgtcactcagaccccaaaattc	SEQ ID No: 2
TRAV12-2	gcccagccggccatggcccagaaggaggtggagcagaattc	SEQ ID No: 3
TRAV21	gcccagccggccatggccaaacaggaggtgacgcagattcc	SEQ ID No: 4
YOL237	gagtctctcagctggtacacgg	SEQ ID No: 5
YOL240	agtgtggccttttgggtgtg	SEQ ID No: 6
YOL236	ccgtgtaccagctgagagactc	SEQ ID No: 7
YOL238	gcgcgctgtgagaatagaaag	SEQ ID No: 8
YOL239	cacacccaaaaggccacact	SEQ ID No: 9

Figure 3
ELISA screening of a pooled TRAV 12.2/21 TRBV 6* library panned with 4 different peptide HLA antigens. CMV indicates negative control antigen.




Figure 4
ELISA screening of a pooled TRAV 12.2/21 TRBV 6* library prepared from a single HLA-A2/A24 negative donor and panned with 3 peptide HLA antigens. CMV indicates negative control antigen




Figure 5
ELISA screening of individual TRAV 12.2 TRBV 6* / TRAV21 TRBV 6* libraries panned with 2 peptide HLA antigens. CMV indicates negative control antigen




Figure 6

ELISA screening of individual TRAV 12.2 TRBV 6* / TRAV21 TRBV 6* libraries prepared from a commercial mRNA source and panned with 2 peptide HLA antigens. CMV indicates negative control antigen






Figure 7
Specificity testing of TCRs isolated from a library of the invention



* Positive control

Figure 8

Biacore binding curves for soluble versions of antigen specific TCRs isolated from a library of the invention

Antigen 2 TCRs**Antigen 3 TCRs**